fluorouracil and Cancer, Second Primary studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

Excerpt	Relevance	Reference
"The purpose was to compare disease-free survival (DFS) between epirubicin-based chemoendocrine therapy and tamoxifen alone in one to three node-positive (N1-3), estrogen-receptor-positive (ER+), postmenopausal early breast cancer (EBC) patients."	9.12	Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 ( Bonneterre, J; Campone, M; Fargeot, P; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P, 2006)
"The French Adjuvant Study Group 05 (FASG-05) showed that fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 100 mg/m2 (FEC 100) was superior to the same regimen with epirubicin 50 mg/m2 (FEC 50) in terms of disease-free survival (DFS) and overall survival (OS) in adjuvant treatment of early breast cancer."	9.11	Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. ( Bonneterre, J; Brémond, A; Chapelle-Marcillac, I; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Namer, M; Roché, H; Schraub, S, 2005)
"After 5 years of follow-up, the increased epirubicin dose led to a significant benefit in terms of DFS and OS, with a high survival rate among patients with poor-prognosis breast cancer."	9.09	Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. ( , 2001)
"The purpose of this study was to evaluate incidence and risk factors of secondary leukemia after adjuvant epirubicin-based chemotherapy in breast cancer patients."	8.82	Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. ( Bonneterre, J; Campone, M; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P, 2005)
" The current study aimed to retrospectively investigate neoadjuvant radiotherapy with cisplatin and 5-fluorouracil (CF-RT) and radiotherapy with docetaxel and CF (DCF-RT) and compare their treatment outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC)."	8.12	Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. ( Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Nakajo, A; Noda, M; Ohtsuka, T; Sasaki, K; Shimonosono, M; Tsuruda, Y; Uchikado, Y, 2022)
"We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer."	7.80	An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. ( Goto, M; Ishiyama, S; Kojima, Y; Komiyama, H; Niwa, K; Okuzawa, A; Sakamoto, K; Sugimoto, K; Takahashi, M; Tomiki, Y; Yaginuma, Y, 2014)
"We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple-negative metastatic breast cancer previously treated with anthracyclines and taxanes."	7.76	Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report. ( Bosković, L; Curić, Z; Lukić, B; Mise, BP; Tica, I; Vrdoljak, E, 2010)
"This study retrospectively evaluates the occurrence of second hematological and solid malignancies in the context of a prospective multicenter phase III trial comparing epirubicin-cyclophosphamide at intermediate doses (EC), or at full doses (HEC), with classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 777 patients with early breast cancer."	7.72	Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer ( Accettura, C; Bernard-Marty, C; Cardoso, F; Di Leo, A; Kleiber, K; Larsimont, D; Lobelle, JP; Mano, M; Munoz-Bermeo, R; Paesmans, M; Piccart, MJ; Richard, T, 2003)
"We retrospectively analyzed patients referred to our hospital for AML with a past history of polychemotherapy for breast cancer, including mitoxantrone, either as adjuvant (8 patients)/neoadjuvant (1 patient) therapy or for metastatic disease (1 patient)."	7.70	Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. ( Barin, C; Benboubker, L; Binet, C; Brémond, JL; Calais, G; Cartron, G; Colombat, P; Delain, M; Georget, MT; Lamagnère, JP; Leloup, R; Letortorec, S; Linassier, C; Petit, A; Raban, N, 2000)
"Between 1974 and 1989, 1,474 patients with stage II or III breast cancer were treated in six prospective trials of adjuvant (n = 4) or neoadjuvant (n = 2) chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (CTX) (FAC) with or without other drugs."	7.69	Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. ( Buzdar, AU; Diamandidou, E; Frye, D; Hortobagyi, GN; Smith, TL; Witjaksono, M, 1996)
" The rates of severe taxane-related toxic effects and thrombocytopenia, although low overall, are significantly increased with the dose-dense sequential regimen."	6.73	Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008)
"In our 3 patients with metastatic G2 pNETs, STZ/5-FU induced long-term disease control over 44, 42, and 95 months, respectively."	5.72	Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series. ( Keitel, V; Klose, S; Krause, A; Kreissl, MC; Müller, C; Venerito, M, 2022)
"Patients with nonkeratinizing nasopharyngeal carcinoma staged T1-4N2-3M0 were randomly assigned to RT (176 patients) or to CRT (172 patients) using cisplatin (100 mg/m(2)) every 3 weeks for three cycles in concurrence with radiotherapy, followed by cisplatin (80 mg/m(2)) plus fluorouracil (1000 mg per m(2) per day for 4 days) every 4 weeks for three cycles."	5.14	Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. ( Au, GK; Au, JS; Chappell, R; Choi, CW; Chua, DT; Fung, KK; Lau, JT; Lau, WH; Law, SC; Lee, AW; Leung, TW; Ng, WT; Ngan, RK; O'Sullivan, B; Siu, L; Sze, WK; Sze, WM; Tung, R; Tung, SY; Yau, TK, 2010)
"The purpose was to compare disease-free survival (DFS) between epirubicin-based chemoendocrine therapy and tamoxifen alone in one to three node-positive (N1-3), estrogen-receptor-positive (ER+), postmenopausal early breast cancer (EBC) patients."	5.12	Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 ( Bonneterre, J; Campone, M; Fargeot, P; Kerbrat, P; Luporsi, E; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P, 2006)
"Concomitant radiotherapy with adjuvant fluorouracil, mitoxantrone, and cyclophosphamide has significantly better locoregional control in node-positive breast cancer after conservative surgery and 50% shorter treatment, albeit with slightly more acute toxicity."	5.12	A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. ( Bertheault-Cvitkovic, F; Castèra, D; Combe, M; de la Lande, B; Demange, L; Garbay, JR; Graïc, Y; Krzisch, C; Leduc, B; Lucas, V; Mouret-Fourme, E; Nguyen, TD; Noguès, C; Rouëssé, J; Serin, D; Villet, R, 2006)
"The French Adjuvant Study Group 05 (FASG-05) showed that fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 100 mg/m2 (FEC 100) was superior to the same regimen with epirubicin 50 mg/m2 (FEC 50) in terms of disease-free survival (DFS) and overall survival (OS) in adjuvant treatment of early breast cancer."	5.11	Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. ( Bonneterre, J; Brémond, A; Chapelle-Marcillac, I; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Namer, M; Roché, H; Schraub, S, 2005)
"After 5 years of follow-up, the increased epirubicin dose led to a significant benefit in terms of DFS and OS, with a high survival rate among patients with poor-prognosis breast cancer."	5.09	Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. ( , 2001)
"Between 1976 and 1984, 574 patients with operable breast cancer and histologically negative axillary lymph nodes were randomly assigned after mastectomy to receive either no further treatment or chemotherapy with oral LMF (fluorouracil, 500 mg, methotrexate, 25 mg, and chlorambucil, 10 mg, on day 1; fluorouracil, 500 mg, and chlorambucil, 10 mg, on day 2)."	5.07	West Midlands Oncology Association trial of adjuvant chemotherapy in node-negative breast cancer. ( Grieve, RJ; Howell, A; Kelly, KA; Monypenny, IJ; Morrison, JM; Walker, RA; Waterhouse, JA, 1992)
"The purpose of this study was to evaluate incidence and risk factors of secondary leukemia after adjuvant epirubicin-based chemotherapy in breast cancer patients."	4.82	Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. ( Bonneterre, J; Campone, M; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Romestaing, P, 2005)
" The current study aimed to retrospectively investigate neoadjuvant radiotherapy with cisplatin and 5-fluorouracil (CF-RT) and radiotherapy with docetaxel and CF (DCF-RT) and compare their treatment outcomes in patients with locally advanced esophageal squamous cell carcinoma (ESCC)."	4.12	Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. ( Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Nakajo, A; Noda, M; Ohtsuka, T; Sasaki, K; Shimonosono, M; Tsuruda, Y; Uchikado, Y, 2022)
" The combination of epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan was originally designed for the treatment of metastatic colorectal cancer."	3.83	Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report. ( Chai, CY; Chien, TM; Huang, CN; Lin, CH; Lu, YM, 2016)
"We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer."	3.80	An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. ( Goto, M; Ishiyama, S; Kojima, Y; Komiyama, H; Niwa, K; Okuzawa, A; Sakamoto, K; Sugimoto, K; Takahashi, M; Tomiki, Y; Yaginuma, Y, 2014)
"5T) was performed in 191 female CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil) chemotherapy-exposed breast cancer survivors."	3.77	Incidental findings on brain Magnetic Resonance Imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy. ( Boogerd, W; Breteler, MM; Koppelmans, V; Poels, MM; Schagen, SB; Seynaeve, C; van der Lugt, A, 2011)
"We report an extremely long duration of chemotherapy with ixabepilone and capecitabine (42 cycles) in a patient with triple-negative metastatic breast cancer previously treated with anthracyclines and taxanes."	3.76	Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report. ( Bosković, L; Curić, Z; Lukić, B; Mise, BP; Tica, I; Vrdoljak, E, 2010)
"A 59-year-old patient with a coexisting primary choroidal melanoma and colorectal cancer was treated with external beam radiation (EBR) of his choroidal melanoma and systemic chemotherapy with leukovorin/5 fluorouracil (FU) for treatment of his metastatic colorectal cancer."	3.74	Regression of radiation-induced macular edema after systemic bevacizumab. ( Bakri, SJ; Pulido, JS; Solano, JM, 2007)
"The associations between chemotherapy and tamoxifen treatment and reduced risk for contralateral breast cancer appear to continue for 10 and 5 years, respectively, after the initial breast cancer is diagnosed."	3.74	Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. ( Anton-Culver, H; Begg, CB; Bernstein, JL; Bernstein, L; Bertelsen, L; Boice, JD; Capanu, M; Christensen, J; Ejlertsen, B; Haile, RW; Langholz, B; Lynch, CF; Malone, KE; Mellemkjaer, L; Olsen, JH; Shore, RE; Stovall, M; Thomas, DC, 2008)
"We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil."	3.73	t(8;16) AML developed subsequent to breast cancer therapy. ( Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z, 2006)
"This study retrospectively evaluates the occurrence of second hematological and solid malignancies in the context of a prospective multicenter phase III trial comparing epirubicin-cyclophosphamide at intermediate doses (EC), or at full doses (HEC), with classical cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in 777 patients with early breast cancer."	3.72	Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer ( Accettura, C; Bernard-Marty, C; Cardoso, F; Di Leo, A; Kleiber, K; Larsimont, D; Lobelle, JP; Mano, M; Munoz-Bermeo, R; Paesmans, M; Piccart, MJ; Richard, T, 2003)
"A 62-year-old male patient who developed Philadelphia chromosome-positive chronic myeloid leukemia (CML) after cisplatin and 5-fluorouracil treatment for colon adenocarcinoma is reported."	3.71	Chronic myeloid leukemia in a patient with colon adenocarcinoma. ( Gokel, Y; Paydas, S, 2002)
"We retrospectively analyzed patients referred to our hospital for AML with a past history of polychemotherapy for breast cancer, including mitoxantrone, either as adjuvant (8 patients)/neoadjuvant (1 patient) therapy or for metastatic disease (1 patient)."	3.70	Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. ( Barin, C; Benboubker, L; Binet, C; Brémond, JL; Calais, G; Cartron, G; Colombat, P; Delain, M; Georget, MT; Lamagnère, JP; Leloup, R; Letortorec, S; Linassier, C; Petit, A; Raban, N, 2000)
"Between 1974 and 1989, 1,474 patients with stage II or III breast cancer were treated in six prospective trials of adjuvant (n = 4) or neoadjuvant (n = 2) chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide (CTX) (FAC) with or without other drugs."	3.69	Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. ( Buzdar, AU; Diamandidou, E; Frye, D; Hortobagyi, GN; Smith, TL; Witjaksono, M, 1996)
"Thirty patients with advanced metastatic breast cancer were treated with 5-fluorouracil."	3.64	5-Fluorouracil in metastatic mammary cancer. ( DEMAREE, EW; MOORMAN, HD, 1962)
"Standard treatment of locally advanced rectal cancer (LARC) was neoadjuvant chemoradiotherapy (CRT), followed by total mesorectal excision (TME)."	3.30	Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial. ( Bai, S; Cai, P; Chang, H; Chen, G; Gao, Y; Liu, S; Luo, H; Pan, Z; Wang, Q; Wang, X; Wu, X; Xiao, W; Ye, Y; Yu, H; Zeng, Z; Zhuang, Y, 2023)
"Patients with stage III/IV resectable head and neck squamous cell carcinoma were randomized to surgery followed by RT or CCRT."	2.80	Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. ( Ang, MK; Hwang, J; Iyer, NG; Lim, WT; Sivanandan, R; Soo, KC; Tan, DS; Tan, EH; Tan, HK; Tan, NC; Tan, VK; Wang, W; Wee, J, 2015)
" The rates of severe taxane-related toxic effects and thrombocytopenia, although low overall, are significantly increased with the dose-dense sequential regimen."	2.73	Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. ( Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008)
"Patients with recurrent squamous cell carcinoma or a second primary arising in a previously irradiated field were eligible."	2.73	Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. ( Ang, KK; Harris, J; Machtay, M; Meredith, R; Rotman, M; Schultz, C; Spanos, W; Spencer, SA; Wheeler, RH, 2008)
"Patients with intermediate-stage squamous cell carcinoma of the head and neck traditionally have been treated with initial surgical resection followed by radiotherapy (RT) alone or chemoradiotherapy."	2.72	High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. ( Brockstein, B; Cohen, EE; Haraf, DJ; Kies, MS; Kocherginsky, M; List, MA; Mittal, BB; Rosen, F; Stenson, KM; Vokes, EE; Williams, R; Witt, ME, 2006)
"Of the total patients, 47% had stage II colon cancer, and 53% had stage III colon cancer."	2.72	Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. ( Colangelo, LH; Colman, LK; Giguere, JK; Jacobs, AD; Lembersky, BC; Marshall, ME; O'Connell, MJ; Petrelli, NJ; Seay, TE; Smith, RE; Soran, A; Wieand, HS; Wolmark, N; Yothers, G, 2006)
"These findings suggest that colorectal cancer with aneuploidy and a DI above 1."	2.68	Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer. ( Hoshino, K; Kaibara, N; Kimura, O; Kurayoshi, K; Makino, M; Sugezawa, A, 1995)
"Patients with locally recurrent head and neck cancer previously treated with radiation have a poor prognosis."	2.43	Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? ( Li, Y; Machtay, M; Wong, SJ, 2006)
"For metastatic breast cancer, the dose and schedule associated with the most favorable therapeutic index for paclitaxel was 175 mg/m2 given as a 3-hour infusion every 3 weeks, and docetaxel was 60-100 mg/m2 given as a 1-hour infusion every 3 weeks."	2.41	Rationale and use of epirubicin-based therapy in the adjuvant setting. ( Mouridsen, HT, 2000)
"In our 3 patients with metastatic G2 pNETs, STZ/5-FU induced long-term disease control over 44, 42, and 95 months, respectively."	1.72	Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series. ( Keitel, V; Klose, S; Krause, A; Kreissl, MC; Müller, C; Venerito, M, 2022)
"Most frequent second cancers were prostate cancer (18."	1.72	Second Cancer After Additive Chemotherapy in Patients With Colon Cancer. ( Ebert, MP; Evert, M; Gerken, M; Herr, W; Klinkhammer-Schalke, M; Li, M; Schlitt, HJ; Teufel, A, 2022)
"Metastatic colorectal cancer is associated with poor overall survival and limited treatment options."	1.56	Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. ( Alawi, M; David, K; Ewald, F; Fischer, L; Indenbirken, D; Izbicki, JR; Jücker, M; Juhl, H; Molloy, MP; Nashan, B; Omidi, M; Sauter, G; Schlüter, H; Simon, R; Smit, DJ; Spohn, M; Voß, H; Wurlitzer, M, 2020)
"Data were analyzed from a prospective pancreatic cancer database."	1.48	Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. ( Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA, 2018)
" We compared tolerability and efficacy of the two different chemotherapy regimens; 5-FU/leucovorin (LV) versus cisplatin with capecitabine (XP) combined with radiotherapy (RT) in the adjuvant therapy of the lymph node positive locally advanced gastric cancer."	1.48	Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer. ( Bilici, A; Erkol, B; Figen, M; Surmelioglu, A; Tilki, M; Ustaalioglu, BBO; Uyar, S, 2018)
"The involvement of S-1 chemotherapy in ATLL development suggests that a test for HTLV-1 antibody should be performed before treatment and that S-1 should not be administered in HTLV-1 positive patients with head and neck carcinoma."	1.46	Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy. ( Kurono, Y; Matushita, K; Nagano, H, 2017)
"We analyzed data of mspHNSCC patients collected from the Taiwan Cancer Registry database."	1.46	Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma. ( Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS, 2017)
"Patients with ovarian cancer are at increased risk of SPM development."	1.42	Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan: A Nationwide Population-Based Study. ( Chao, Y; Chen, MH; Chen, TJ; Chiou, TJ; Hu, YW; Hung, YP; Li, CP; Liu, CJ; Yang, MH; Yeh, CM, 2015)
"Different treatments for cervical cancer, including radiotherapy (HR 1."	1.42	Secondary Primary Malignancy Risk in Patients With Cervical Cancer in Taiwan: A Nationwide Population-Based Study. ( Chao, Y; Chen, TJ; Hu, YW; Hung, YP; Huon, LK; Liu, CJ; Teng, CJ; Yang, MH; Yeh, CM, 2015)
"The clinicopathological data of 110 gastric cancer patients who developed recurrence or second primary malignancies after radical gastrectomy and adjuvant chemotherapy with FOLFOX4 regimen or docetaxel plus FOLFOX4 regimen were analyzed retrospectively."	1.42	[Characteristics of recurrence in patients with gastric cancer after radical gastrectomy and adjuvant chemotherapy]. ( Du, C; Guo, C; Wang, J; Xu, Q; Zhou, A, 2015)
"In recent decades, the management of rectal cancer has been significantly improved by optimizing the surgical treatment with the total mesorectal excision and the development of neoadjuvant radiotherapy with or without chemotherapy."	1.42	[Preoperative chemoradiotherapy for rectal cancer: experience from one centre]. ( Bednarek, C; Bosset, JF; Cerda, T; Guimas, V; Lepinoy, A; Lescut, N; Schipman, B, 2015)
"We discuss the association between esophageal cancer and subsequent second malignancies, along with implications for surveillance and therapy."	1.40	Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer. ( Dasanu, CA; Nandy, N, 2014)
"Gastric cancer was diagnosed as CR(complete response)in gastroscopy after 6 courses of chemotherapy."	1.38	[The chemotherapy with mFOLFOX6 for advanced colon cancer was effective for gastric cancer - a case report]. ( Asakage, M; Muto, Y; Shimoishi, K; Yamada, Y, 2012)
"Gastric cancer is the third most common cancer worldwide and the second leading cause of cancer deaths."	1.37	Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer. ( Abou-Alfa, GK; Al-Olayan, A; Kelsen, D; Lowery, M; Naghy, M; Power, D; Saliba, T; Shah, MA; Shamseddine, A; Smyth, E, 2011)
"Interestingly, rare balanced chromosomal abnormalities were observed in the present cases, thus providing new insights into the leukemogenesis of therapy-related leukemia."	1.36	Therapy-related leukemia following chemoradiotherapy for esophageal cancer. ( Ise, M; Kumagai, K; Mimura, N; Nagata, M; Sakai, C; Takagi, T; Tsujimura, H, 2010)
"A patient with inflammatory breast carcinoma (IBC) diagnosed in the left breast responded to cisplatin and was treated with radical mastectomy and adjuvant therapy."	1.35	Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab. ( Amorós, A; Casinello, J; Heredia, M; Lázaro, A; López-Alfonso, A, 2008)
"After 10 years, second primary cancer (seven cases) became as important an issue as recurrence of primary gastric cancer (six cases)."	1.34	Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. ( Chung, HC; Jeung, HC; Kim, BS; Moon, YW; Noh, SH; Rha, SY; Roh, JK; Yoo, NC, 2007)
"Currently, a large population of breast cancer survivors is at increased risk of death from CVDs and second cancers, especially when treated with RT at a young age."	1.33	Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. ( Aleman, BM; Hooning, MJ; Klijn, JG; Kuenen, MA; van Leeuwen, FE; van Rosmalen, AJ, 2006)
"Early changes in karyotype detected in breast cancer patients following ASCT are transient and do not correlate with or predict development of MDS/AML."	1.31	Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome. ( Arbona, C; Benet, I; Comes, AM; García Clavel, B; García-Conde, J; Lluch, A; Martínez-Climent, JA; Marugán, I; Prósper, F; Solano, C; Vizcarra, E, 2000)
"Two patients were diagnosed with large rectal tumors and localized prostate cancer."	1.31	External beam radiotherapy for synchronous rectal and prostatic tumors. ( Kapp, DS; King, C; Siu, W; Terris, MK; Wren, SM, 2001)
"We reviewed the records of 223 patients treated for T3--4 squamous cell carcinoma of the larynx between October 1, 1957, and December 1, 1999."	1.31	Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. ( Fu, KK; Goffinet, DR; Le, QT; Nguyen-Tan, PF; Quivey, JM; Singer, M; Terris, DJ, 2001)
"Cytogenetic abnormalities were not found in the stem cell harvests of these patients by metaphase analysis or by fluorescence in situ hybridization (FISH)."	1.31	Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. ( de Castro, K; Griffin, M; Hesdorffer, C; Lin, N; Murty, VV; Nichols, G; Oratzi, A; Troxel, A; Vahdat, L; Wei, LX, 2002)
"Nine non-breast cancers were observed versus 2."	1.30	Cancer risk after adjuvant chemo- or chemohormonal therapy of breast cancer. ( Hirvikoski, PP; Johansson, RT; Kumpulainen, EJ; Pukkala, E, 1998)
"Melphalan (MEL) was the only drug used in single-drug chemotherapy."	1.29	Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants. ( Friberg, LG; Granberg, S; Islam, MQ; Köpf, I; Levan, A; Levan, G, 1993)
" In CCR managed with EC, the independent factors of age, tumor classification, exact tumor location, true vocal cord motion, arytenoid cartilage motion, total dosage of drugs delivered, and number of courses received were tested for potential correlation with survival, local recurrence, nodal recurence, and distant metastasis."	1.29	Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results. ( Bassot, V; Brasnu, D; Khayat, D; Laccourreye, H; Laccourreye, O; Ménard, M, 1996)

Research

Studies (124)

Authors

Clinical Trials (8)

Trial Overview

Trial Outcomes

Toxicity

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.81)	18.7374
1990's	22 (17.74)	18.2507
2000's	49 (39.52)	29.6817
2010's	41 (33.06)	24.3611
2020's	11 (8.87)	2.80

Authors	Studies
Reher, D	1
Fehrenbach, U	1
Kayser, A	1
Pape, UF	1
Henes, FO	1
Cremer, B	1
Hörsch, D	1
Izbicki, J	1
Lohse, AW	1
Rinke, A	1
Schrader, J	1
Müller, C	1
Kreissl, MC	1
Klose, S	1
Krause, A	1
Keitel, V	1
Venerito, M	1
Nishiwaki, N	1
Noma, K	1
Kunitomo, T	1
Hashimoto, M	1
Maeda, N	1
Tanabe, S	1
Sakurama, K	1
Shirakawa, Y	1
Fujiwara, T	1
Sasaki, K	1
Tsuruda, Y	1
Shimonosono, M	1
Noda, M	1
Uchikado, Y	1
Arigami, T	1
Matsushita, D	1
Mori, S	1
Nakajo, A	1
Kurahara, H	1
Ohtsuka, T	1
Teufel, A	1
Li, M	1
Gerken, M	1
Ebert, MP	1
Schlitt, HJ	1
Evert, M	1
Herr, W	1
Klinkhammer-Schalke, M	1
van den Berg, K	1
Schaap, DP	1
Voogt, ELK	1
Buffart, TE	1
Verheul, HMW	1
de Groot, JWB	1
Verhoef, C	1
Melenhorst, J	1
Roodhart, JML	1
de Wilt, JHW	1
van Westreenen, HL	1
Aalbers, AGJ	1
van 't Veer, M	1
Marijnen, CAM	1
Vincent, J	1
Simkens, LHJ	1
Peters, NAJB	1
Berbée, M	1
Werter, IM	1
Snaebjornsson, P	1
Peulen, HMU	1
van Lijnschoten, IG	1
Roef, MJ	1
Nieuwenhuijzen, GAP	1
Bloemen, JG	1
Willems, JMWE	1
Creemers, GJM	1
Nederend, J	1
Rutten, HJT	1
Burger, JWA	1
Lv, T	1
Shen, L	1
Xu, X	1
Yao, Y	1
Mu, P	1
Zhang, H	1
Wan, J	1
Wang, Y	2
Guan, R	1
Li, X	1
Fu, G	1
Zhang, L	1
Xia, F	1
Hu, C	1
Clevers, H	1
Zhang, Z	1
Hua, G	1
Liu, S	1
Wang, X	1
Zhuang, Y	1
Bai, S	1
Wu, X	1
Ye, Y	1
Luo, H	1
Yu, H	1
Wang, Q	1
Chang, H	1
Zeng, Z	1
Cai, P	1
Pan, Z	1
Gao, Y	1
Chen, G	1
Xiao, W	1
Otta-Oshiro, RJ	1
Lista-Mateos, F	1
Encinas-García, S	1
Morales-García, S	1
Núñez-Mora, C	1
Cornejo, CM	1
Jambusaria-Pahlajani, A	1
Willenbrink, TJ	1
Schmults, CD	1
Arron, ST	1
Ruiz, ES	1
Voß, H	1
Wurlitzer, M	1
Smit, DJ	1
Ewald, F	1
Alawi, M	1
Spohn, M	1
Indenbirken, D	1
Omidi, M	1
David, K	1
Juhl, H	1
Simon, R	1
Sauter, G	1
Fischer, L	1
Izbicki, JR	1
Molloy, MP	1
Nashan, B	1
Schlüter, H	1
Jücker, M	1
Pich, O	1
Cortes-Bullich, A	1
Muiños, F	1
Pratcorona, M	1
Gonzalez-Perez, A	1
Lopez-Bigas, N	1
Kluger, MD	1
Rashid, MF	1
Rosario, VL	1
Schrope, BA	1
Steinman, JA	1
Hecht, EM	1
Chabot, JA	1
Kassar, O	1
Mseddi, S	1
Mdhaffer, M	1
Bellaaj, H	1
Mnif, S	1
Ghorbel, M	1
Sennena, H	1
Elloumi, M	1
Ustaalioglu, BBO	1
Bilici, A	1
Tilki, M	1
Surmelioglu, A	1
Erkol, B	1
Figen, M	1
Uyar, S	1
Siegel, JA	1
Beatson, M	1
Chren, MM	1
Weinstock, MA	1
Takeuchi, M	1
Kawakubo, H	1
Mayanagi, S	1
Yoshida, K	1
Irino, T	1
Fukuda, K	1
Nakamura, R	1
Wada, N	1
Takeuchi, H	1
Kitagawa, Y	1
Lyons, AB	1
Mitchell, DA	1
Moy, RL	1
Kerscher, AG	1
Chua, TC	1
Gasser, M	1
Maeder, U	1
Kunzmann, V	1
Isbert, C	1
Germer, CT	1
Pelz, JO	1
Rashidi, A	2
Man, L	1
Howard, JR	1
Atienza, D	1
Fisher, SI	2
Lamberth, F	1
Guilbert, P	1
Gaillot-Petit, N	1
Champagne, C	1
Looten-Vieren, L	1
Nguyen, TD	2
Nandy, N	1
Dasanu, CA	1
Grey, A	1
Cooper, A	1
McNeil, C	1
O'Toole, S	1
Thompson, J	1
Grimison, P	1
Takahashi, M	2
Niwa, K	1
Ishiyama, S	1
Sugimoto, K	1
Komiyama, H	1
Yaginuma, Y	1
Kojima, Y	1
Goto, M	1
Okuzawa, A	1
Tomiki, Y	1
Sakamoto, K	1
Amarillo, I	1
Iyer, NG	1
Tan, DS	1
Tan, VK	1
Wang, W	1
Hwang, J	1
Tan, NC	1
Sivanandan, R	1
Tan, HK	1
Lim, WT	1
Ang, MK	1
Wee, J	1
Soo, KC	1
Tan, EH	1
Lescut, N	1
Lepinoy, A	1
Schipman, B	1
Cerda, T	1
Guimas, V	1
Bednarek, C	1
Bosset, JF	1
Dartigues, P	1
Hung, YP	2
Liu, CJ	2
Hu, YW	2
Chen, MH	1
Li, CP	1
Yeh, CM	2
Chiou, TJ	1
Chen, TJ	2
Yang, MH	2
Chao, Y	2
Teng, CJ	1
Huon, LK	1
Du, C	1
Guo, C	1
Xu, Q	1
Wang, J	1
Zhou, A	1
Lu, YM	1
Chien, TM	1
Lin, CH	1
Chai, CY	1
Huang, CN	1
Nagano, H	1
Kurono, Y	1
Matushita, K	1
Chen, JH	1
Yen, YC	1
Chen, TM	1
Yuan, KS	1
Lee, FP	1
Lin, KC	1
Lai, MT	1
Wu, CC	1
Chang, CL	1
Wu, SY	1
Sakaguchi, M	1
Maebayashi, T	1
Aizawa, T	1
Ishibashi, N	1
Saito, T	1
Lázaro, A	1
Casinello, J	1
Amorós, A	1
Heredia, M	1
López-Alfonso, A	1
Gutweiler, JR	1
Yu, DC	1
Kim, HB	1
Kozakewich, HP	1
Marcus, KJ	1
Shamberger, RC	1
Weldon, CB	1
Tardío, JC	1
Nájera, L	1
Alemany, I	1
Martín, T	1
Castaño, A	1
Pérez-Regadera, JF	1
Küronya, Z	1
Bodrogi, I	1
Lövey, J	1
Plótár, V	1
Manninger, S	1
Pápai, Z	1
Willems, L	1
Suarez, F	1
Messas, E	1
Baubion, N	1
Decaudin, D	1
Fourquet, A	1
Ghez, D	1
Delarue, R	1
Hermine, O	1
Buzyn, A	1
Varet, B	1
Rubio, MT	1
Otsuka, S	1
Inagaki, M	1
Nishie, M	1
Hamano, R	1
Tokunaga, N	1
Takahashi, K	2
Tsunemitsu, Y	1
Miyoshi, K	1
Iwakawa, K	1
Iwagak, H	1
Kara, O	1
Ozdemir, E	1
Arslan, C	1
Dogan, E	1
Altundag, K	1
Vrdoljak, E	1
Mise, BP	1
Lukić, B	1
Curić, Z	1
Bosković, L	1
Tica, I	1
Maleux, G	1
Vaninbroukx, J	1
Heye, S	1
van Cutsem, E	1
Oyen, R	1
Frikha, M	1
Toumi, N	1
Ghorbel, L	1
Ben Salah, H	1
Khabir, A	1
Karray, H	1
Gargouri, R	1
Boudawara, T	1
Ghorbel, A	1
Daoud, J	1
Smyth, E	1
Abou-Alfa, GK	1
Lowery, M	1
Shamseddine, A	1
Al-Olayan, A	1
Naghy, M	1
Power, D	1
Saliba, T	1
Kelsen, D	1
Shah, MA	1
Mimura, N	1
Tsujimura, H	1
Ise, M	1
Sakai, C	1
Takagi, T	1
Nagata, M	1
Kumagai, K	1
Lee, AW	1
Tung, SY	1
Chua, DT	1
Ngan, RK	1
Chappell, R	1
Tung, R	1
Siu, L	1
Ng, WT	1
Sze, WK	1
Au, GK	1
Law, SC	1
O'Sullivan, B	1
Yau, TK	1
Leung, TW	1
Au, JS	1
Sze, WM	1
Choi, CW	1
Fung, KK	1
Lau, JT	1
Lau, WH	1
Shien, K	1
Yamashita, M	1
Okazaki, M	1
Suehisa, H	1
Sawada, S	1
Miyoshi, S	1
Kawaguchi, Y	1
Nishiyama, K	1
Miyagi, K	1
Suzuki, O	1
Ito, Y	1
Nakamura, S	1
Choe, KS	1
Haraf, DJ	4
Solanki, A	1
Cohen, EE	2
Seiwert, TY	1
Stenson, KM	4
Blair, EA	1
Portugal, L	1
Villaflor, VM	1
Witt, ME	4
Vokes, EE	4
Salama, JK	3
Koppelmans, V	1
Schagen, SB	1
Poels, MM	1
Boogerd, W	1
Seynaeve, C	1
van der Lugt, A	1
Breteler, MM	1
Rai, K	1
Fujiwara, K	1
Tsushima, M	1
Kudo, K	1
Mizuta, M	1
Matsuo, K	2
Yonei, T	2
Yamadori, I	1
Kiura, K	2
Sato, T	1
Choda, Y	1
Ninomiya, M	1
Fujiwara, Y	1
Kanazawa, T	1
Harano, M	1
Matsukawa, H	1
Ojima, Y	1
Shiozaki, S	1
Ohno, S	1
Shimoishi, K	1
Muto, Y	1
Asakage, M	1
Yamada, Y	1
Nakashima, S	1
Hatanaka, N	1
Yoshikawa, Y	1
Tominaga, H	1
Sunada, S	1
Shimizu, Y	1
Endo, S	1
Nishitani, A	1
Hiraoka, K	1
Irei, T	1
Takahashi, H	1
Boku, M	1
Wakahara, M	1
Kamiike, W	1
Taniyama, K	1
Gardini, A	1
Saragoni, L	1
La Barba, G	1
Serra, L	1
Calistri, D	1
Ulivi, P	1
Casadei, A	1
Frassineti, GL	1
Garcea, D	1
Nichols, G	1
de Castro, K	1
Wei, LX	1
Griffin, M	1
Lin, N	1
Oratzi, A	1
Murty, VV	1
Troxel, A	1
Vahdat, L	1
Hesdorffer, C	1
Bogenrieder, T	1
Weitzel, C	1
Schölmerich, J	1
Landthaler, M	1
Stolz, W	1
Mace, AD	1
Lale, AM	1
Capper, JW	1
Maruyama, K	1
Maruyama, N	1
Tanaka, J	1
Nakamura, M	1
Katsumoto, Y	1
Yokouchi, H	1
Nakaguchi, K	1
Furukawa, J	1
Sue, F	1
Bernard-Marty, C	1
Mano, M	1
Paesmans, M	1
Accettura, C	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
"Neo-adjuvant FOLFOXIRI and Chemoradiotherapy for High Risk (Ugly) Locally Advanced Rectal Cancer"[NCT04838496]	Phase 2	128 participants (Anticipated)	Interventional	2021-06-01	Not yet recruiting
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study[NCT05277766]	Phase 1	45 participants (Anticipated)	Interventional	2022-11-21	Recruiting
Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation[NCT00970502]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2007-02-28	Completed
Phase III Randomized Controlled Clinical Study of UFT/LV Therapy Versus UFT/LV + PSK Therapy as Postoperative Adjuvant Therapy for Histological Stage IIIa and IIIb Colorectal Cancer[NCT00497107]	Phase 3	300 participants (Anticipated)	Interventional	2007-07-31	Recruiting
A Clinical Trial Comparing Oral Uracil/Ftorafur (UFT) Plus Leucovorin (LV) With 5-Fluorouracil (5-FU) Plus LV in the Treatment of Patients With Stages II And III Carcinoma of the Colon[NCT00378716]	Phase 3	1,608 participants (Actual)	Interventional	1997-02-28	Completed
Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck[NCT00002951]	Phase 2	53 participants (Actual)	Interventional	1996-06-30	Completed
Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders[NCT01525927]	Phase 2	2 participants (Actual)	Interventional	2010-08-31	Terminated (stopped due to Principal Investigator left institution. IRB approval lapsed.)
Adjuvant Dose-dense Sequential Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel or Weekly Paclitaxel in Patients With Resected High-risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study[NCT04829890]		89 participants (Actual)	Observational	2004-02-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Number of participants with acute and late toxicity (NCT00970502)
Timeframe: 30 DAYS

Clinical Response

Intervention	participants (Number)
Celecoxib 200mg	0
Celecoxib 400mg	1
Celecoxib 600mg	2

Response to Concurrent Erlotinib, Celecoxib, and Reirradiation according to Response Evaluation Criteria in Solid Tumors - Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions (NCT00970502)
Timeframe: 20 months

Locoregional Control, Progression-free Survival, Overall Survival and Late Toxicity

Intervention	Participants (Count of Participants)
	Complete Response(CR)	Pathologic partial response (pPR)	Progressive disease (PD)	No evidence of disease (NED)
Erlotinib + Celecoxib	6	1	5	2

At a median follow-up of 11 months, the 1 year locoregional control, progression-free survival, and overall survival rates. (NCT00970502)
Timeframe: 1 year

Locoregional Progression

Intervention	percentage of participants (Number)
	locoregional control	progress-free survival	overall survival rates	long term toxicity
Erlotinib + Celecoxib	60	37	55	0

Patients with locoregional and/or distant progression (NCT00970502)
Timeframe: 20 months

Intervention	participants (Number)
	free of disease	isolated locoregional progression	isolated distant progression	both locoregional and distant progression	no evidence of disease, died of comorbid illness
Erlotinib + Celecoxib	4	4	2	1	3

Article	Year
Field cancerization: Treatment. Journal of the American Academy of Dermatology, 2020, Volume: 83, Issue:3 Topics: Administration, Cutaneous; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Carcinogenesi	2020
[Peritoneal tumor pathology - case no. 3 : peritoneal well-differentiated papillary mesothelioma]. Annales de pathologie, 2015, Volume: 35, Issue:4 Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor	2015
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group. Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan	2005
Locally recurrent, previously irradiated head and neck cancer: concurrent re-irradiation and chemotherapy, or chemotherapy alone? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-10, Volume: 24, Issue:17 Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Fluorouracil; Head and Neck Neoplasms; H	2006
Secondary acute lymphoblastic leukaemia following oxaliplatin for adjuvant chemotherapy in colon cancer. Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc	2008
Case report: Second primary small cell carcinoma of the trachea in a breast cancer survivor: a case report and literature review. The British journal of radiology, 2008, Volume: 81, Issue:964 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Duct	2008
Rationale and use of epirubicin-based therapy in the adjuvant setting. Clinical breast cancer, 2000, Volume: 1 Suppl 1 Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo	2000

Article	Year
Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT). BMC cancer, 2022, Sep-06, Volume: 22, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Clinical Trials, Ph	2022
Total neoadjuvant treatment to increase the clinical complete response rate for distal locally advanced rectal cancer (TESS): A study protocol of a prospective, open-label, multicenter, single-arm, phase 2 trial. Cancer medicine, 2023, Volume: 12, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Clinical Trials, Ph	2023
Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis. Cancer, 2015, May-15, Volume: 121, Issue:10 Topics: Adult; Aged; Alphapapillomavirus; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamou	2015
Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. Journal of the National Cancer Institute, 2010, Aug-04, Volume: 102, Issue:15 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp	2010
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. International journal of radiation oncology, biology, physics, 2005, Mar-15, Volume: 61, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols	2005
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-20, Volume: 23, Issue:12 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan	2005
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Br	2006
A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. International journal of radiation oncology, biology, physics, 2006, Mar-15, Volume: 64, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan	2006
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-01, Volume: 24, Issue:13 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms	2006
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-01, Volume: 24, Issue:13 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms	2006
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-01, Volume: 24, Issue:13 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms	2006
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, May-01, Volume: 24, Issue:13 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms	2006
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jul-20, Volume: 24, Issue:21 Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamo	2006
Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head & neck, 2008, Volume: 30, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous	2008
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:3 Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols;	2008
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5 Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci	2008
Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer. Surgery today, 1995, Volume: 25, Issue:3 Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; H	1995
Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:1 Topics: Adult; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Th	1995
Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:9 Topics: Actuarial Analysis; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast	1994
Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small cell lung cancer. A phase 2 study of the LCSG. Chest, 1994, Volume: 106, Issue:6 Suppl Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat	1994
The effect of adjuvant prednisone combined with CMF on patterns of relapse and occurrence of second malignancies in patients with breast cancer. International (Ludwig) Breast Cancer Study Group. Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:3 Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; C	1996
Breast conserving therapy in stage I & II breast cancer in Korea. Breast cancer research and treatment, 1997, Volume: 44, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The	1997
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Feb-01, Volume: 19, Issue:3 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan	2001
West Midlands Oncology Association trial of adjuvant chemotherapy in node-negative breast cancer. Journal of the National Cancer Institute. Monographs, 1992, Issue:11 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chlorambuc	1992

Article	Year
Localization Defines Streptozotocin/5-FU Response in Primary Pancreatic Neuroendocrine Tumours. Neuroendocrinology, 2022, Volume: 112, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoplasms, Second Primary; Neu	2022
Long-term treatment with streptozocin/5-fluorouracil chemotherapy in patients with metastatic pancreatic neuroendocrine tumors: Case series. Medicine, 2022, Jan-28, Volume: 101, Issue:4 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Male; Middle Aged; Neopl	2022
Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis. Esophagus : official journal of the Japan Esophageal Society, 2022, Volume: 19, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage	2022
Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. Anticancer research, 2022, Volume: 42, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophage	2022
Second Cancer After Additive Chemotherapy in Patients With Colon Cancer. Clinical colorectal cancer, 2022, Volume: 21, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluoroura	2022
Patient-derived tumor organoids predict responses to irinotecan-based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. International journal of cancer, 2023, 02-01, Volume: 152, Issue:3 Topics: Chemoradiotherapy; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Neoplasms, Second Primary;	2023
Metachronous Signet Ring Cell Bladder Metastasis as First Sing of Cancer Recurrence. Urology, 2019, Volume: 134 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Chemotherapy, Adj	2019
Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. Clinical & experimental metastasis, 2020, Volume: 37, Issue:6 Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Extracellular Matrix; Extracel	2020
The evolution of hematopoietic cells under cancer therapy. Nature communications, 2021, 08-10, Volume: 12, Issue:1 Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clonal Evolution; C	2021
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2018, Volume: 22, Issue:2 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemo	2018
Chronic myeloid leukemia following the treatment of nasopharyngeal carcinoma. La Tunisie medicale, 2017, Volume: 95, Issue:3 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Female;	2017
Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer. Journal of cancer research and therapeutics, 2018, Volume: 14, Issue:Supplement Topics: Adult; Aged; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Diseas	2018
Effects of new keratinocyte carcinomas on skin-related quality of life: Results from the Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial. Journal of the American Academy of Dermatology, 2019, Volume: 80, Issue:5 Topics: Antimetabolites, Antineoplastic; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Chemoprevention; C	2019
The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma. World journal of surgery, 2019, Volume: 43, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; C	2019
Topical chemotherapy for numerous superficial basal cell carcinomas years after isolated limb perfusion for melanoma. Cutis, 2019, Volume: 103, Issue:5 Topics: Administration, Cutaneous; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents	2019
Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades. British journal of cancer, 2013, Apr-16, Volume: 108, Issue:7 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort S	2013
Therapy-related acute promyelocytic leukemia after chemoradiotherapy with capecitabine for rectal adenocarcinoma. Leukemia & lymphoma, 2014, Volume: 55, Issue:3 Topics: Antimetabolites, Antineoplastic; Bone Marrow; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Leu	2014
[Potential indications for helical tomotherapy in breast cancers]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2014, Volume: 18, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brea	2014
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer. JOP : Journal of the pancreas, 2014, Jan-10, Volume: 15, Issue:1 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad	2014
Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma. Internal medicine journal, 2014, Volume: 44, Issue:6 Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diseas	2014
An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. Journal of medical case reports, 2014, Jun-26, Volume: 8 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma;	2014
BRCA2-associated therapy-related acute myeloid leukemia. Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Duct	2015
[Preoperative chemoradiotherapy for rectal cancer: experience from one centre]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2015, Volume: 19, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Pro	2015
Secondary Primary Malignancy Risk in Patients With Ovarian Cancer in Taiwan: A Nationwide Population-Based Study. Medicine, 2015, Volume: 94, Issue:38 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Comorbidity; Female; Fluorouracil; Humans; In	2015
Secondary Primary Malignancy Risk in Patients With Cervical Cancer in Taiwan: A Nationwide Population-Based Study. Medicine, 2015, Volume: 94, Issue:43 Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Comorbidity; Female; Fluorouracil; Humans; Middle A	2015
[Characteristics of recurrence in patients with gastric cancer after radical gastrectomy and adjuvant chemotherapy]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2015, Volume: 37, Issue:8 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Fluorouracil; Gas	2015
Epidermal growth factor receptor inhibitor with fluorouracil, leucovorin, and irinotecan as an alternative treatment for advanced upper tract urothelial carcinoma: a case report. Journal of medical case reports, 2016, Apr-18, Volume: 10 Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorect	2016
Adult T-cell leukemia/lymphoma in patients with head and neck cancer after S-1 chemotherapy. Auris, nasus, larynx, 2017, Volume: 44, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C	2017
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma. Cancer medicine, 2017, Volume: 6, Issue:1 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell;	2017
Clinical Outcomes of Hypopharyngeal Cancer Receiving Definitive Radiotherapy with Concurrent Chemotherapy. Anticancer research, 2017, Volume: 37, Issue:2 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deglutition Diso	2017
Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:9 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas	2008
Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma. Journal of pediatric surgery, 2008, Volume: 43, Issue:12 Topics: Adrenal Gland Neoplasms; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas	2008
Rectal angiosarcoma after adjuvant chemoradiotherapy for adenocarcinoma of the rectum. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27 Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fatal Outcome; Fluorouracil	2009
[Metachronous metastasis from rectal adenocarcinoma to the penis--case report]. Magyar onkologia, 2009, Volume: 53, Issue:3 Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb	2009
[High risk of cardiac dysfunction after treatment of secondary acute myeloid leukemia following chemotherapy and radiotherapy for breast cancer]. Bulletin du cancer, 2010, Volume: 97, Issue:2 Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy	2010
[A case of pathological complete response of metachronous multiple liver metastases from colorectal cancer after mFOLFOX+bevacizumab chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12 Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Ant	2009
Acute promyelocytic leukemia in a young patient with breast cancer. Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubici	2011
Long-lasting control of triple-negative metastatic breast cancer with the novel drug combination ixabepilone and capecitabine--case report. Onkologie, 2010, Volume: 33, Issue:1-2 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; C	2010
Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy. Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:6 Topics: Aneurysm; Angiogenesis Inhibitors; Angiomyolipoma; Antibodies, Monoclonal; Antibodies, Monoclonal, H	2010
[Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities]. Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2010, Volume: 14, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adju	2010
Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer. Journal of gastrointestinal cancer, 2011, Volume: 42, Issue:1 Topics: Adenocarcinoma; Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin	2011
Therapy-related leukemia following chemoradiotherapy for esophageal cancer. European journal of haematology, 2010, Volume: 85, Issue:4 Topics: Aged; Antineoplastic Agents; Chromosome Aberrations; Chromosomes, Human, Pair 5; Combined Modality T	2010
Primary lung cancer surgery after curative chemoradiotherapy for esophageal cancer patients. Interactive cardiovascular and thoracic surgery, 2011, Volume: 12, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C	2011
Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous	2011
Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation. Cancer, 2011, Oct-15, Volume: 117, Issue:20 Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antineoplastic Combined Chemotherapy Protocols; Ch	2011
Incidental findings on brain Magnetic Resonance Imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy. European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:17 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brea	2011
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations. Japanese journal of clinical oncology, 2011, Volume: 41, Issue:9 Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomark	2011
[A case report of multiple adenocarcinoma in small intestine after total gastrectomy by Roux-en-Y re-construction]. Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluorouracil; Gastrectomy	2011
[The chemotherapy with mFOLFOX6 for advanced colon cancer was effective for gastric cancer - a case report]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluorouracil; Human	2012
[Long-term survival of a case of advanced cancer of the esophagogastric junction with complete response to low-dose 5-fluorouracil and cisplatin chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Esophagogastric Jun	2012
Challenge in differential diagnosis of a liver mass histologically defined as a metastatic lesion from an occult primary intestinal tumour. The importance of clinical findings and the limitations of histology and molecular profiles. A case report. Pathologica, 2012, Volume: 104, Issue:4 Topics: Adenoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intr	2012
Therapy-related myelodysplastic syndrome after autologous stem cell transplantation for breast cancer. Leukemia, 2002, Volume: 16, Issue:9 Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, D	2002
Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma? Dermatology (Basel, Switzerland), 2002, Volume: 205, Issue:2 Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Colorectal Neoplasms	2002
Adenocarcinoma of the ethmoid sinuses: a case of two primary tumours. The Journal of laryngology and otology, 2002, Volume: 116, Issue:9 Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Ethmoid Sinus; Fluoro	2002
[A case of esophageal cancer successfully treated by chemoradiotherapy after resection for multiple liver metastasis of sigmoid colon cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12 Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Infus	2002
Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:5 Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Belgium; B	2003
Chronic myeloid leukemia in a patient with colon adenocarcinoma. Haematologia, 2002, Volume: 32, Issue:4 Topics: Adenocarcinoma; Cisplatin; Colonic Neoplasms; Fluorouracil; Humans; Leukemia, Myelogenous, Chronic,	2002
5-Fluorouracil in metastatic mammary cancer. California medicine, 1962, Volume: 97 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Fluorouracil; Humans; Middle	1962
[Evaluation of arterial infusion chemotherapy for liver metastasis from gastric cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administrat	2003
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. International journal of radiation oncology, biology, physics, 2006, Feb-01, Volume: 64, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality	2006
Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. International journal of radiation oncology, biology, physics, 2006, Mar-15, Volume: 64, Issue:4 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cardiovascular Diseas	2006
Subtotal hepatectomy following neoadjuvant chemotherapy for a previously unresectable hepatocellular carcinoma. Journal of hepato-biliary-pancreatic surgery, 2006, Volume: 13, Issue:4 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Hepa	2006
Comparison of local recurrence and distant metastases between breast cancer patients after postmastectomy radiotherapy with and without immediate TRAM flap reconstruction. Plastic and reconstructive surgery, 2006, Volume: 118, Issue:5 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Comb	2006
Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer. British journal of cancer, 2006, Nov-06, Volume: 95, Issue:9 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phas	2006
Clinically occult cutaneous metastases. Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:6 Topics: Aged; Aged, 80 and over; Anastrozole; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormon	2006
t(8;16) AML developed subsequent to breast cancer therapy. Hematology (Amsterdam, Netherlands), 2006, Volume: 11, Issue:3 Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone M	2006
Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. Annals of surgical oncology, 2007, Volume: 14, Issue:10 Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;	2007
Regression of radiation-induced macular edema after systemic bevacizumab. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2007, Volume: 42, Issue:5 Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetab	2007
Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. Journal of the National Cancer Institute, 2008, Jan-02, Volume: 100, Issue:1 Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl	2008
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma. Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:4 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; De	2008
Ethmoid sinus leiomyosarcoma after cyclophosphamide treatment. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 1995, Volume: 113, Issue:4 Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Ch	1995
[Leukemia in patients with breast carcinoma after adjuvant chemotherapy and/or postoperative radiotherapy]. Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1995, Volume: 171, Issue:7 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan	1995
[A case of meningeal carcinomatosis which occurred after treatment for recurrence of the cervical carcinoma]. Nihon Sanka Fujinka Gakkai zasshi, 1995, Volume: 47, Issue:1 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combine	1995
Influence of cisplatinum and 5-fluorouracil on the oral mucosa. European journal of cancer. Part B, Oral oncology, 1994, Volume: 30B, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cisplatin; Fluorour	1994
[A case of secondary leukemia induced by chemotherapy with a CDDP-based regimen for gastric cancer 5 years following radical resection]. Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:1 Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Gastrectomy; Humans	1993
Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants. Cancer genetics and cytogenetics, 1993, Volume: 65, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chil	1993
Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols	1996
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox	1996
Carcinoma of the esophagus treated with radical chemoradiation 19 years after irradiation for recurrent breast cancer. Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 1997, Volume: 10, Issue:2 Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamou	1997
Secondary leukemia after autologous peripheral blood progenitor cell transplantation for breast cancer. Leukemia, 1997, Volume: 11, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyc	1997
[Resuscitation necessitated by a transfusion reaction after HLA mismatched platelets substitution]. Beitrage zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine, 1994, Volume: 32 Topics: Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cyt	1994
Cancer risk after adjuvant chemo- or chemohormonal therapy of breast cancer. Anti-cancer drugs, 1998, Volume: 9, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast	1998
The effectiveness of chemotherapy with cisplatin and 5-fluorouracil for recurrent small cell neuroendocrine carcinoma of the rectum: report of a case. Surgery today, 1999, Volume: 29, Issue:2 Topics: Adenoma, Villous; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Carcino	1999
Therapy related acute myeloid leukemia after exposure to 5-fluorouracil: a case report. Hematology and cell therapy, 1999, Volume: 41, Issue:5 Topics: Acute Disease; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Leukemia, Myeloid; Mid	1999
Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome. Bone marrow transplantation, 2000, Volume: 25, Issue:11 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemotherapy,	2000
Wide-field radiation as adjunct to adjuvant chemotherapy in high-risk cases with early breast cancer: do it or not? International journal of cancer, 2000, Aug-01, Volume: 87, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cause of Death; Chemotherapy, Adju	2000
Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The	2000
Undifferentiated leukemia following treatment of gastric cancer with 5 fluorouracil, doxorubicin, mitomycin C chemotherapy. The Journal of the Association of Physicians of India, 2000, Volume: 48, Issue:6 Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow;	2000
External beam radiotherapy for synchronous rectal and prostatic tumors. Urology, 2001, Volume: 57, Issue:4 Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Fluorouracil; Follow-Up Studies; Humans; Male; Neoplas	2001
Treatment results and prognostic factors of advanced T3--4 laryngeal carcinoma: the University of California, San Francisco (UCSF) and Stanford University Hospital (SUH) experience. International journal of radiation oncology, biology, physics, 2001, Aug-01, Volume: 50, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Carcinom	2001
Second primary cardiac B-cell lymphoma after radiation therapy and chemotherapy--a case report. Angiology, 2001, Volume: 52, Issue:8 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cisp	2001
Myelodysplastic syndrome/acute myelogenous leukaemia after adjuvant chemotherapy with pyrimidine anti-metabolites in three patients. Haematologica, 2001, Volume: 86, Issue:10 Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Fluorouracil; Humans; Le	2001
Chemotherapy alone with curative intent in patients with invasive squamous cell carcinoma of the pharyngolarynx classified as T1-T4N0M0 complete clinical responders. Cancer, 2001, Sep-15, Volume: 92, Issue:6 Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Therapy, Combination; F	2001
Advanced head and neck cancer: long-term results of chemo-radiotherapy, complications and induction of second malignancies. Onkologie, 2001, Volume: 24, Issue:6 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cobalt Radioisotopes; Combined Moda	2001
Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Annals of internal medicine, 2002, Feb-19, Volume: 136, Issue:4 Topics: Adenoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Colonic Neoplasms;	2002
Primary breast cancer after prophylactic mastectomy. American journal of clinical oncology, 1991, Volume: 14, Issue:5 Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Mod	1991

fluorouracil and Cancer, Second Primary